Advanced search
Publication Cover
Acta Orthopaedica Volume 83, 2012 - Issue 5
Journal homepage
1,450
Views
26
CrossRef citations to date
0
Altmetric
Case report

Atypical femoral fracture following bisphosphonate treatment in a woman with osteogenesis imperfecta—a case report

Raphael P H Meier Department of Surgery
,
Kuntheavy Ing Lorenzini Division of Clinical Pharmacology and Toxicology
,
Brigitte Uebelhart Division of Bone Diseases, Department of Medical Specialties,
,
Richard Stern Division of Orthopedic Surgery, Department of Surgery, University Hospitals of Geneva, and Faculty of Medicine, Geneva, Switzerland
,
Robin E Peter Division of Orthopedic Surgery, Department of Surgery, University Hospitals of Geneva, and Faculty of Medicine, Geneva, Switzerland
&
René Rizzoli Division of Bone Diseases, Department of Medical Specialties,Correspondence[email protected]
Pages 548-550 | Received 09 Feb 2012, Accepted 29 Jun 2012, Published online: 24 Sep 2012

  • Funds were recieved from University Hospitals of Geneva.
  • Adami S, Gatti D, Colapietro F, Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 2003; 18 (1): 126-30.
  • Bornemann MSaxon JR,Kidd GS 2nd. Osteoporosis unmasked by hyperthyroidism in a young man with osteogenesis imperfecta. Arch Intern Med 1987; 147 (11): 1947-8.
  • DiMeglio LA,Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res 2006; 21 (1): 132-40.
  • Durchschlag E, Paschalis EP, Zoehrer R, Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 2006; 21 (10): 1581-90.
  • Gatti D, Antoniazzi F, Prizzi R, Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 2005; 20 (5): 758-63.
  • Ing-Lorenzini K, Desmeules J, Plachta O, Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 2009; 32 (9): 775-85.
  • Letocha AD, Cintas HL, Troendle JF, Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 2005; 20 (6): 977-86.
  • Mashiba T, Turner CH, Hirano T, Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001; 28 (5): 524-31.
  • Mashiba T, Mori S, Burr DB, The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 2005;23:(Suppl)36-42.
  • Meier RP, Perneger TV, Stern R, Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 2012; 172 (12): 930-6.
  • Pauwels F. Die Bedeutung der Bauprinzipien des Stutz-und Bewegungsapparates fur die Beanspruchung der Röhrenknochen. Z Anat Entwicklungsgesch 1948; 114 (1-2): 129-66.
  • Phillipi CA, Remmington T, Steiner RD. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 2008; (4): CD005088.
  • Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004; 363 (9418): 1377-85.
  • Rizzoli R, Akesson K, Bouxsein M, Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011; 22 (2): 373-90.
  • Sakkers R, Kok D, Engelbert R, Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 2004; 363 (9419): 1427-31.
  • Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011; 364 (18): 1728-37.
  • Seikaly MG, Kopanati S, Salhab N, Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop 2005; 25 (6): 786-91.
  • Shabat S. Osteogenesis imperfecta-induced migratory stress fractures in a military recruit. Clin Exp Rheumatol 2000; 18 (5): 654.
  • Shane E, Burr D, Ebeling PR, Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010; 25 (11): 2267-94.
  • Spotila LD, Constantinou CD, Sereda L, Mutation in a gene for type I procollagen (COL1A2) in a woman with postmenopausal osteoporosis: evidence for phenotypic and genotypic overlap with mild osteogenesis imperfecta. Proc Natl Acad Sci U S A 1991; 88 (12): 5423-7.
  • Tan SC, Koh SB, Goh SK, Atypical femoral stress fractures in bisphosphonate-free patients. Osteoporos Int 2011; 22 (7): 2211-2.
  • Visekruna MWilson D,McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metsb 2008; 93 (8): 2948-52.
  • Wekre LL, Froslie KF, Haugen L, A population-based study of demographical variables and ability to perform activities of daily living in adults with osteogenesis imperfecta. Disabil Rehabil 2010; 32 (7): 579-87.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.